Raymond James Upgrades Medexus Pharmaceuticals (TSE:MDP) to Strong-Buy

Medexus Pharmaceuticals (TSE:MDP) was upgraded by research analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research report issued on Wednesday, Marketbeat reports. The brokerage presently has a C$4.00 price target on the stock. Raymond James’ price objective would indicate a potential downside of 1.72% from the company’s current price. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

MDP has been the subject of a number of other research reports. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Two equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Medexus Pharmaceuticals has an average rating of “Strong Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Stock Up 13.1 %

MDP stock opened at C$4.07 on Wednesday. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$4.07. The firm has a market cap of C$99.84 million, a price-to-earnings ratio of 81.40 and a beta of 1.96. The business’s fifty day simple moving average is C$2.74 and its two-hundred day simple moving average is C$2.52.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.